Stem Cell Assurance Announces Appointment of Mark Weinreb, M.S. as Chief Executive Officer and Board Member

BOCA RATON, Florida, October 19, 2010 - Stem Cell Assurance, Inc. (Pink Sheets: SCLZ) announced today the
appointment of Mark Weinreb as Chief Executive Officer and as a member of the
Company's Board of Directors. Mr. Weinreb is a well-recognized and respected
professional within the medical and financial communities.

Mr. Weinreb offers expertise in public (President and CEO of AMEX and
NASDAQ listed companies) and private corporate management, in the areas of
healthcare, medical devices, research programs, franchising, and
business/product development. Mr. Weinreb was most recently President and a
director of NeoStem, Inc., a public biotechnology medical services company
specializing in enhancing the delivery of adult stem cell therapeutics and
developing an international network of adult stem cell collection centers.

Mr. Weinreb also was an owner and operator of BioHealth Laboratories,
Inc., a leading diagnostic state-of-the-art medical laboratory providing
clinical testing services for physicians, hospitals, and other medical
laboratories. He was educated at Northwestern University and C.W. Post (Long
Island University).

Gloria McConnell, President of Stem Cell Assurance, stated, "We are
extremely pleased and fortunate to have a seasoned entrepreneur and executive
of Mr. Weinreb's caliber become so excited about our Company that he has
accepted our offer to become our full time chief executive officer and
provide his leadership skills in growing the Company's business."

Said Mr. Weinreb, "I believe the Company's business has tremendous
potential, and I very much look forward to embarking on an aggressive growth
strategy that will position the Company to capitalize on current and future
therapeutic uses of adult stem cells."

About Stem Cell Assurance, Inc.

Stem Cell Assurance, Inc.'s goal is to become a medical center of
excellence using cell and tissue regenerative therapy protocols, primarily
involving a patient's own (autologous) adult stem cells (non-embryonic),
allowing patients to undergo cellular-based treatments. As more and more
cellular therapies become standard of care, the Company believes its strength
will be its focus on the unity of medical and scientific explanations for its
future clinical procedures and outcomes and its incorporation of adult stem
cell collection and storage services for future personal medical
applications. The Company intends to offer, through its "Lipo Rejuvenation
Centers," the collection of adipose tissue for use in cosmetic treatments and
for the separation and storage of adult stem cells. The Company also operates
a wholly-owned subsidiary, Stem Cellutrition(TM), which offers and sells
facial creams and products.

This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. You are cautioned that
such statements are subject to a multitude of risks and uncertainties that
could cause future circumstances, events or results to differ materially from
those projected in the forward-looking statements as a result of various
factors and other risks. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as
of the date hereof and the Company undertakes no obligation to update such
statements.

    CONTACT
    Gloria McConnell
    President
    Tel: +1-561-362-4142
    Fax: +1-561-362-4451
    E-mail: gloriamcconnell@stemcellassurance.com

Gloria McConnell, President of Stem Cell Assurance, Inc., +1-561-362-4142, or Fax, +1-561-362-4451, gloriamcconnell at stemcellassurance.com